echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: The effect of enzalutamide in mCRPC patients in the elderly is better than that of abiraterone acetate

    Eur J Cancer: The effect of enzalutamide in mCRPC patients in the elderly is better than that of abiraterone acetate

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly


    This study aims to compare the clinical efficacy and tolerability of AA and enzalutamide in mCRPC patients 80 years and older


    This is a retrospective propensity-weighted comparative cohort study that recruited mCRPC patients over 80 years of age who were treated with first-line AA or enzalutamide


    A) The time from the start of treatment to the progression of PSA; B) The time before any progression; C) The time before treatment failure; D) Overall survival rate

    A) The time from the start of treatment to the progression of PSA; B) The time before any progression; C) The time before treatment failure; D) Overall survival rate

    A total of 278 patients were enrolled, of which 153 were treated with AA and 125 were treated with enzalutamide


    Enzalutamide treatment is associated with a higher PSA remission rate and TTP , but not related to TTPP.


    Enzalutamide is associated with a higher PSA response rate and longer time to progression Enzalutamide is associated with a higher PSA response rate and longer time to progression

    Original source:

    Original source:

    Soleimani Maryam,Zou Kevin,Sunderland Katherine et al.


    Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.